To validate these findings, in situ hybridization assays were conducted to detect SPRY4-IT1 expression in 113 clinical colorectal cancer, 101 breast cancer, and 96 ovarian cancer tissue samples (Fig. 1C). This evidence concerns the gene SPRY4 and ovarian cancer.